On September 15, Ionis Pharmaceuticals fell 6.29% in regular trading, trading at $48.20 per share, with turnover of approximately $95.42 million, extending its recent downtrend.

The decline reflects persistent selling pressure following two major cardiovascular pipeline setbacks. On September 8, pelacarsen, a heart disease drug co-developed with Novartis, failed to meet its primary endpoint in a late-stage clinical trial, triggering a 13% pre-market plunge that day. Earlier in July, Eplontersen, developed in partnership with AstraZeneca for transthyretin-mediated amyloid cardiomyopathy, also failed its Phase 3 primary efficacy endpoint, which had sent shares down over 20% in a single session. The consecutive failures of two key cardiovascular programs have significantly eroded market confidence in the company's core R&D capabilities.

Notably, analysts have been trimming price targets in response. BofA recently lowered its target to $91 from $93, while RBC cut its target to $85 from $100 following the July setback. Despite these reductions, the current share price of $48.19 trades well below the analyst consensus target of approximately $84, reflecting a deep disconnect between analyst views and investor sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)